--- title: "Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider Losses - Has The Bull Case Changed?" type: "News" locale: "en" url: "https://longbridge.com/en/news/284977345.md" description: "Summit Therapeutics Inc. reported a widening net loss of $189.4 million for Q1 2026, with a loss per share of $0.24. The company is advancing Phase III trials for ivonescimab and has received FDA acceptance for its Biologics License Application, with a PDUFA goal date of November 14, 2026. The upcoming overall survival data from the HARMONi-6 trial is critical for the company's future, as rising losses and cash burn pose risks. Analysts project significant revenue growth by 2029, but the reliance on a single drug raises concerns about investment viability." datetime: "2026-05-02T22:07:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284977345.md) - [en](https://longbridge.com/en/news/284977345.md) - [zh-HK](https://longbridge.com/zh-HK/news/284977345.md) --- # Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider Losses - Has The Bull Case Changed? - Summit Therapeutics Inc. has reported first quarter 2026 results, with net loss widening to US$189.4 million and basic and diluted loss per share from continuing operations at US$0.24, while also advancing multiple Phase III trials of ivonescimab in non-small cell lung cancer and colorectal cancer. - The company’s upcoming presentation of overall survival data from the pivotal Phase III HARMONi-6 trial at the ASCO 2026 Plenary Session, together with the FDA’s acceptance of its Biologics License Application for ivonescimab in EGFR-mutated non-small cell lung cancer and a PDUFA goal date set for November 14, 2026, marks a critical point for its lead asset’s clinical and regulatory profile. - With HARMONi-6 overall survival data now headed to an ASCO Plenary, we’ll examine how this could reshape Summit’s investment narrative. Outshine the giants: these 18 early-stage AI stocks could fund your retirement. ## Summit Therapeutics Investment Narrative Recap To own Summit Therapeutics today, you have to believe ivonescimab can clear key regulatory bars and translate its broad Phase III program into a viable commercial product, despite steep current losses. The widening first quarter 2026 net loss to US$189.4 million does not directly change the near term clinical catalyst, which remains the upcoming HARMONi-6 overall survival data and the FDA’s ivonescimab BLA review, but it does sharpen the immediate financing and cash burn risk. The most relevant recent announcement is the FDA’s acceptance of Summit’s Biologics License Application for ivonescimab in EGFR mutated non small cell lung cancer, with a PDUFA goal date of November 14, 2026. This filing, alongside the HARMONi-6 overall survival data heading to an ASCO Plenary, concentrates attention on whether a single asset can justify the company’s heavy investment and underpin future funding options if the current losses persist. Yet behind the excitement around HARMONi-6, investors should be aware that rising losses and a finite cash runway could force hard choices if... Read the full narrative on Summit Therapeutics (it's free!) Summit Therapeutics' narrative projects $848.4 million revenue and $125.2 million earnings by 2029. This implies an earnings increase of about $1.2 billion from -$1.1 billion today. Uncover how Summit Therapeutics' forecasts yield a $29.18 fair value, a 81% upside to its current price. ## Exploring Other Perspectives SMMT 1-Year Stock Price Chart Before this earnings hit, the most optimistic analysts were modeling about US$3.1 billion of revenue and US$1.7 billion of earnings by 2029, which is a far brighter scenario than the consensus view. Given how dependent that bullish case is on one drug across many trials, this latest loss and the coming HARMONi 6 survival readout could push those expectations in very different directions, so it is worth weighing how comfortable you are with such a wide spread in possible outcomes. Explore 7 other fair value estimates on Summit Therapeutics - why the stock might be worth over 5x more than the current price! ## Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. - A great starting point for your Summit Therapeutics research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision. - Our free Summit Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Summit Therapeutics' overall financial health at a glance. ## Looking For Alternative Opportunities? Early movers are already taking notice. See the stocks they're targeting before they've flown the coop: - We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. - Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. - Uncover the next big thing with 24 elite penny stocks that balance risk and reward. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Beam Therapeutics Q1 net loss narrows beating analyst estimates](https://longbridge.com/en/news/285537693.md) - [Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 | SMMT Stock News](https://longbridge.com/en/news/284831367.md) - [Evercore ISI Sticks to Their Buy Rating for Summit Therapeutics (SMMT)](https://longbridge.com/en/news/284912082.md) - [Tyler Van Buren Reiterates Buy on Summit Therapeutics, Citing Stable Long-Term Sales Outlook and Attractive Risk/Reward Despite Higher Future OpEx](https://longbridge.com/en/news/285420620.md) - [Summit's Q1 Net Loss Widens; Expects Patient Enrollment In Phase III ILLUMINE Study In Q2,2026](https://longbridge.com/en/news/284871928.md)